Description
Jpleprill (Enalapril Maleate) 10 mg
Jpleprill 10 mg is a tablet medicine containing enalapril maleate, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is an established cardiovascular medicine used mainly to lower blood pressure and, in selected patients, to support treatment of heart failure and left ventricular dysfunction.
Active Ingredient and Medicine Class
The verified active ingredient is enalapril maleate. It belongs to the ACE inhibitor class of antihypertensive medicines. Enalapril is a prodrug, meaning it is converted in the body to its active form, enalaprilat.
Established Medical Uses
Official prescribing information recognises enalapril maleate tablets for the treatment of hypertension. It is also used in symptomatic congestive heart failure and in clinically stable patients with asymptomatic left ventricular dysfunction, where it can help reduce progression to overt heart failure and lower hospitalisation risk.
These are established uses for the active ingredient; the exact regulatory status of the trade name Jpleprill may vary by country.
How It Works
Enalapril lowers the activity of ACE, an enzyme involved in the renin-angiotensin-aldosterone system. This reduces formation of angiotensin II, a substance that narrows blood vessels and promotes sodium and water retention. The result is less vascular resistance and reduced workload on the heart. Enalaprilat, the active metabolite, is responsible for the main pharmacological effect.
Important Safety Information
Enalapril should not be used in patients with a history of angioedema related to previous ACE inhibitor treatment. It is contraindicated in pregnancy because medicines that act on the renin-angiotensin system can cause fetal harm. Co-administration with aliskiren is contraindicated in patients with diabetes, and dual blockade of the renin-angiotensin system can increase the risk of hypotension, kidney dysfunction and high potassium levels.
Important precautions include reduced kidney function, dehydration or salt depletion, prior angioedema, and use with medicines that may raise potassium or affect renal function. Clinically significant interactions can occur with potassium-sparing diuretics, potassium supplements, NSAIDs, lithium, and certain immunosuppressive or mTOR-inhibitor therapies. Blood pressure, kidney function and serum potassium may be affected during therapy.
Possible Side Effects
Commonly reported adverse effects include dizziness, low blood pressure, cough, headache and fatigue. Some patients may experience changes in kidney function or elevated potassium.
Serious but less common reactions include angioedema, severe hypotension, worsening renal function, hyperkalemia and rare liver-related adverse effects. Any swelling of the face, lips, tongue or throat is medically urgent.
Scientific Evidence
Human clinical and review literature supports enalapril as an effective ACE inhibitor that reduces blood pressure without a compensatory rise in heart rate. Reviews also describe benefit in heart failure, including improvement in symptoms and haemodynamic measures in selected patients. More recent review evidence in children notes that enalapril is used in paediatric hypertension, heart failure and chronic kidney disease, although the evidence base is less complete in younger children and in some heart-failure settings.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official patient leaflet, product label or an individual assessment by a qualified healthcare professional.
Medical Sources
- DailyMed / FDA Enalapril Maleate Tablets, USP. Official prescribing information. View prescribing information
- DailyMed / FDA Enalapril Maleate oral solution. Official prescribing information. View prescribing information
- H J Gomez et al. Enalapril: a review of human pharmacology. Drugs, 1985. View scientific article
- P A Todd et al. Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs, 1986. View scientific article
- Nori J L Smeets et al. Pharmacology of enalapril in children: a review. Drug Discovery Today, 2020. View scientific article